Arog Pharmaceuticals, Inc.

This study tested a new drug, crenolanib, against an existing drug, midostaurin, in adults aged 18-60 with a specific genetic type of acute myeloid leukemia (FLT3-mutated AML). Participants received one of the two drugs alongside standard chemotherapy and, if eligible, a bone mar…

This study tested whether adding a targeted drug called crenolanib to standard chemotherapy could better control a specific type of acute myeloid leukemia (AML) that had returned or not responded to prior treatment. It involved 106 adults aged 75 or younger whose cancer had a spe…